Result of General Meeting

Renalytix PLC

08 June 2023

 

 Renalytix plc  

("Renalytix" or the "Company")

Result of General Meeting

LONDON and SALT LAKE CITY, June 8, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that at the General Meeting ("GM") held earlier today all resolutions were passed. Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 11 May 2023.

The results of the GM are detailed below:

Resolution	In Favour Votes	%		Against Votes	%		Withheld Votes
1	35,540,650	98.8%		439,984	1.2%		62,458
2	35,509,132	98.7%		471,662	1.3%		62,298

For further information, please contact:

Renalytix plc	www.renalytix.com
James McCullough, CEO	Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker)	Tel: [phone]
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea
Investec Bank plc (Joint Broker)	Tel: [phone]
Gary Clarence / Shalin Bhamra
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus / Alice Woodings / Lianne Applegarth	Mob: [phone]
CapComm Partners
Peter DeNardo	Tel: [phone] or [e-mail]

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

 

END